Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

Bilirubin acts as a potent endogenous antioxidant, with higher concentrations associated with lower rates of CVD; the antiretroviral drug atazanavir (ATV) increases bilirubin levels but may also increase von Willebrand factor levels. We tested the hypothesis that increasing endogenous bilirubin usin...

Full description

Bibliographic Details
Main Authors: Joshua A Beckman, Brian R Wood, Kevin L Ard, Christin N Price, Daniel A Solomon, Jonah P Zuflacht, Jessica Milian, Joshua C Prenner, Paul E Sax
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0181993

Internet

https://doi.org/10.1371/journal.pone.0181993

Similar Items